Beta-Blockers and Calcium Channel Blockers: First Line Agents
Isaac Pascual1, Cesar Moris1, Pablo Avanzas2
1Área del Corazón, Hospital Universitario Central de Asturias, Avenida de Roma, s/n, 33011, Oviedo, Asturias, Spain.
Cardiovascular Drugs and Therapy
|September 1, 2016
Summary
Beta-blockers and calcium channel blockers (CCB) are recommended first-line treatments for stable coronary ischemic disease and effort-induced angina. These drugs effectively reduce oxygen demand, improving clinical outcomes and remaining guideline-recommended therapies.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Stable coronary ischemic disease management relies on therapies reducing myocardial oxygen demand.
- Beta-blockers and calcium channel blockers (CCB) are established treatments for this condition.
Purpose of the Study:
- To review the established role and continued recommendation of beta-blockers and CCB in treating stable coronary ischemic disease and effort-induced angina.
Main Methods:
- Literature review of clinical guidelines and studies on antianginal therapies.
- Analysis of the pharmacological mechanisms and clinical benefits of beta-blockers and CCB.
Main Results:
- Beta-blockers and CCB effectively reduce myocardial oxygen demand, crucial for managing effort-induced angina.
- Clinical benefits are reproducible, leading to improved overall patient outcomes.
Conclusions:
- Beta-blockers and CCB remain first-line therapies for stable coronary ischemic disease according to current treatment guidelines.
- Despite newer agents, these drugs are recommended due to proven efficacy and safety in managing effort-induced angina.
Related Concept Videos
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.7K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.7K
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
2.1K
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
2.1K
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
2.5K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.5K
01:17Antiepileptic Drugs: Calcium Channel Blockers
1.5K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.5K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
2.2K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.2K
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
1.6K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.6K